CJC-1295 (No DAC) and Ipamorelin are combined into a dual-peptide research formulation developed for laboratory investigation of complementary growth hormone regulatory pathways. CJC-1295 (No DAC) is studied as a GHRH receptor agonist model, while Ipamorelin is researched for its selective interaction with growth hormone secretagogue receptors (GHSR). Together, this peptide blend provides a valuable model for evaluating pituitary signaling, endocrine communication, GH-axis regulation, and IGF-1-associated biological pathways.

This product is supplied exclusively for scientific and preclinical laboratory research.

Product Classification: Research Use Only (RUO)

Total Content: 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin lyophilized powder per vial

Compound: CJC-1295 (No DAC) / Ipamorelin Peptide Blend

Form: Sterile lyophilized peptide blend

Purity: ≥99%

Storage: Store at −20°C in a dry, light-protected environment.

Packaging: Laboratory-grade glass vial.

Intended for laboratory studies involving:

• GHRH receptor pathway research
• Growth hormone secretagogue receptor studies
• Pituitary signaling investigations
• GH-axis interaction models
• IGF-1-associated pathway research
• Dual-peptide signaling analysis
• Endocrine communication studies
• Comparative peptide blend research

For laboratory research only.

Not intended for human or veterinary use.

Abstract

CJC-1295 (No DAC) and Ipamorelin are investigated as complementary peptide models targeting separate components of growth hormone regulation. Laboratory studies focus on GHRH receptor signaling, GHSR-mediated activity, pituitary communication, endocrine pathway interactions, and downstream GH-axis responses.

Mechanistic Pathway

CJC-1295 (No DAC)

Supports laboratory investigation into:

• GHRH receptor activation
• Pituitary signaling
• Growth hormone regulatory pathways

Research Focus: GHRH receptor-associated endocrine communication.

Ipamorelin

Investigated for:

• Growth hormone secretagogue receptor signaling
• Ghrelin receptor pathway models
• Endocrine response mechanisms

Research Focus: GHSR-mediated signaling pathways.

Combined GH-Axis Model

The combination allows researchers to study coordinated activation of GHRH and GHSR signaling within integrated endocrine pathway models.

• Multi-receptor communication
• GH-axis regulation
• Comparative signaling studies

Pharmacokinetics / Research Profile

Research Models

Used exclusively in controlled laboratory settings to investigate receptor signaling and endocrine pathway interactions.

No human or veterinary dosing guidance is provided.

Preclinical Research Highlights

Research applications include:

• Dual receptor pathway analysis
• GH-axis signaling studies
• Pituitary response research
• Endocrine communication models
• IGF-1-associated pathway investigations
• Comparative peptide interaction studies

Conclusion

CJC-1295 (No DAC) combined with Ipamorelin offers researchers a comprehensive dual-peptide model for investigating growth hormone regulation, receptor interaction, and endocrine signaling within preclinical laboratory environments.